The publication of positive Phase 1/2 trial data for DARE-HRT1 is a significant milestone for Daré Bioscience, as it demonstrates the safety and efficacy of the investigational product. This news is likely to have a positive short-term impact on the company's stock price, as it indicates progress in the development of a potentially first-in-category product. The planned Phase 3 clinical trial further supports the potential for future FDA approval and market success.